Impairment related to an asset sale

[Table of Contents](#i40ca88ef65884b508d3f9e19d0380e84_7)NOTE 7 - SUPPLEMENTARY INFORMATION

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Sundry Income (Expense) - Net | Three Months Ended June 30,  |  Six Months Ended June 30,  |  |
| In millions | 2022 | 2021 | 2022 | 2021 |  |  |
| Non-operating pension and other post-employment benefit ("OPEB") credits | $ | 6  |  | $ | 7  |  | $ | 13  |  | $ | 13  |  |  |  |
| Interest income | 2  |  | 5  |  | 3  |  | 9  |  |  |  |
| Net gain on divestiture and sales of other assets and investments 1, 2, 3 | 70  |  | 140  |  | 69  |  | 167  |  |  |  |
| Foreign exchange gains (losses), net  | 9  |  | (10) |  | 4  |  | (16) |  |  |  |
|  |  |  |  |  |  |  |
| Miscellaneous income (expenses) - net 4 | 7  |  | (7) |  | 8  |  | (19) |  |  |  |
| Sundry income (expense) - net | $ | 94  |  | $ | 135  |  | $ | 97  |  | $ | 154  |  |  |  |

1. The three and six months ended June 30, 2022 primarily reflects income of $26 million related to the gain on sale of the Biomaterials business unit and $37 million related to the sale of a land use right within the Water & Protection segment.2. The three and six months ended June 30, 2021 primarily reflects income of $140 million related to the gain on sale of assets within Corporate & Other.3. The six months ended June 30, 2021 reflects income of $24 million related to the gain on sale of assets within the Electronics & Industrial segment.4. The six months ended June 30, 2021 includes an impairment charge of approximately $15 million related to an asset sale.  
Cash, Cash Equivalents and Restricted CashIn connection with the cost sharing arrangement entered into as part of the MOU, the Company is contractually obligated to make deposits into an escrow account to address potential future PFAS costs. At June 30, 2022, the Company had restricted cash of $53 million included within non-current “Restricted cash and cash equivalents” in the Condensed Consolidated Balance Sheets, the majority of which is attributable to the MOU cost sharing arrangement. Additional information regarding the MOU and the escrow account can be found in Note 16.  
Accrued and Other Current Liabilities"Accrued and other current liabilities" in the Condensed Consolidated Balance Sheets were $1,004 million at June 30, 2022 and $1,040 million at December 31, 2021. Accrued payroll, which is a component of "Accrued and other current liabilities," was $285 million at June 30, 2022 and $436 million at December 31, 2021. No other component of "Accrued and other current liabilities" was more than 5 percent of total current liabilities at June 30, 2022 and at December 31, 2021.  
21  

